Check out this new study in Science Magazine by the Sipkins Lab, showing how #BreastCancer cells can use integrin α6 to travel across blood vessels and invade the leptomeninges! Important implications for future treatments. #BCsm The Breast Cancer Research Foundation Duke Cancer science.org/doi/10.1126/sc…

WATCH: Harry Erba, MD, PhD, discusses myeloMATCH, a precision medicine umbrella trial for patients with acute myeloid leukemia or myelodysplastic syndrome. Duke Health Duke Cancer targetedonc.com/view/behind-my…

Duke HMCT has received funding to continue as a core center for the NIH-sponsored Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Dr. Mitchell Horwitz (Mitch Horwitz) is the PI and leads the Duke Consortium including the UVA and Novant Health cell therapy programs.

We have two open faculty positions in adult lymphoma and myeloma within Duke Cancer and additional positions with a lymphoma, myeloma, or MPN focus at our Duke Raleigh Campus site. Please email [email protected] if interested! Hem-Onc Fellows Network medicine.duke.edu/divisions/hema…

New clinical trial now open Duke Cancer: OLYMPIA-3 study evaluating a novel CD3xCD20 bispecific antibody Odronextamab + CHOP for 1st line treatment of #DLBCL. PI is Dr. Jie Wang in the section of lymphoma within Duke Hematologic Malignancies & Cellular Therapy. #lymsm #lymphoma clinicaltrials.gov/study/NCT06091…

A Duke Department of Medicine centennial spotlight on the long and distinguished career of Dr. Nelson Chao, 27 years as division chief of Duke Hematologic Malignancies & Cellular Therapy and former ASTCT president (2005-2006). medicine.duke.edu/news/dom-cente…

New CIBMTR publication in Blood Journal on the real-world outcomes of Axi-cel in DLBCL by race/ethnicity, featuring our new faculty Sanghee Hong as a co-author! #CART #lymsm ashpublications.org/blood/article/…

An important paper featuring Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO on the benefits of a stepped palliative care model for patients with #LungCancer. Stepped-care model => lower care burden with similar #QoL outcomes. #lcsm JAMA pubmed.ncbi.nlm.nih.gov/38824442/

🚨New RN Job Opening Duke Cancer Duke Hematologic Malignancies & Cellular Therapy - Cellular Therapy Coordinator🚨 Join our established team leading Duke's growing commercial CAR-T and TIL program! RN, BSN required; MSN preferred. careers.duke.edu/job-invite/248… Oncology Nursing Society #CART

🎙️ Tune in to the Medscape InDiscussion podcast w/ Duke Hematologic Malignancies & Cellular Therapy faculty Lindsay Rein. Dr. Rein dives into the evolving treatment landscape for #myelofibrosis, discussing JAK inhibitors, transplant options, & more. Don't miss this insightful conversation 🔗 wb.md/46Qt9F2

Important talk by Aravind Ramakrishnan on how to enhance access and safety of outpatient #CART. Personalizing based on patient and product-specific characteristics is critical. Remote monitoring may help! Binaytara Foundation #SCTS24 Duke Hematologic Malignancies & Cellular Therapy will be piloting a novel multi-vital sign

From The ASCO Post "What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?" feat. Danielle M. Brander #PanPacificLymphomaConference Read: bit.ly/4cFj3rJ

Duke is now a Qualified Treatment Center for multiple gene therapies, including #Zynteglo for B-thalassemia and both #Lyfgenia and #Casgevy for sickle cell anemia! 🙏 to the Duke Hematologic Malignancies & Cellular Therapy, Pediatric, and Benign Heme teams for bringing these important treatments to North Carolina!

Check out our national VA Research study of BTK inhibitor use in severe renal failure! No current guidance on FDA labels. #CLLsm British Journal of Haematology 👉 BTK inhibitors feasible even in eGFR < 30 👉⬇️ dose can ⬆️ duration of tx without impacting efficacy onlinelibrary.wiley.com/doi/10.1111/bj…

🎥 Harry Erba (Duke Cancer) provides a comprehensive overview of menin inhibition in AML, discussing the mechanism of action, current key data, and the possibility of predicting the efficacy of these agents in individual patients: 👉 ow.ly/2xq850T9wVb 👈 #AMLsm #Leusm

Take a look at this wonderful reflection piece in Transplantation and Cellular Therapy Journal by our Duke Hematologic Malignancies & Cellular Therapy chief stefanie: "Inspiration From Leaders Who Dare to Care". sciencedirect.com/science/articl…

There is a great need for heme/onc fellowships to teach how to communicate about clinical trials, a paper featuring our own Andrea Sitlinger. The Leukemia & Lymphoma Society supports a workshop at Duke Department of Medicine that does exactly this! #MedEd #disparities pubmed.ncbi.nlm.nih.gov/39104855/

Check out this large U.S. consortium study describing how prior inotuzumab exposure relates to outcomes in patients with #ALL receiving #Tecartus, recently published in Blood Advances and featuring our faculty Chenyu Lin, MD! #ROCCA #leusm #CART 👉pubmed.ncbi.nlm.nih.gov/39093952/👈

Congrats to our outstanding trainees, Katherine Zhou, MD, PhD Duke HemeOnc Fellows and Clare Anderson Duke IM Residency, for their Society of Hematologic Oncology (SOHO) Young Investigator Program scholarships! Here they are presenting their work on lymphoid malignancies at #SOHO24. Mentor(s): Chenyu Lin, MD